Human medicines European public assessment report (EPAR): Lonquex, lipegfilgrastim, Date of authorisation: 25/07/2013, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Palsonify, paltusotine, Date of authorisation: 23/04/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Entyvio, vedolizumab, Date of authorisation: 22/05/2014, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Rimmyrah, ranibizumab, Date of authorisation: 05/01/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Rezzayo, rezafungin, Date of authorisation: 22/12/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 21, Status: Authorised

IRIS guide for applicants - How to create, submit and manage IRIS applications, for industry and individual applicants

IRIS guide to registration and RPIs

Contacting EMA: post-authorisation